YHR007C-A Antibody

What is YHR070C-A protein and why is it significant for research?

YHR070C-A refers to a putative uncharacterized protein found in Saccharomyces cerevisiae (Baker's yeast), specifically in strain 204508/S288c. The significance of studying this protein lies in understanding fundamental cellular processes in this model organism, which has long served as an important eukaryotic research model. Although characterized as "putative uncharacterized," the conservation of this protein in yeast suggests it may have functional importance that remains to be elucidated through targeted research. Investigating proteins like YHR070C-A contributes to our understanding of basic cellular biology, potentially revealing new insights into conserved pathways that may have parallels in higher organisms. Research with this antibody enables scientists to track the expression, localization, and potential interactions of this protein within yeast cells, providing a foundation for functional characterization studies.

What applications is the anti-YHR070C-A antibody validated for?

The rabbit polyclonal anti-YHR070C-A antibody has been validated for specific research applications including ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot analysis. These techniques represent fundamental approaches for protein detection and quantification in molecular biology research. ELISA applications enable researchers to detect and quantify the target protein in complex biological samples, providing data on expression levels across different experimental conditions. Western Blot validation ensures the antibody can specifically recognize the denatured YHR070C-A protein, allowing for size determination and semi-quantitative analysis of protein abundance. The antigen-affinity purification process used in the production of this antibody enhances its specificity for the target protein, reducing background signals and cross-reactivity with other yeast proteins. When designing experiments, researchers should consider the validated applications as primary methodologies, while potentially exploring additional applications following careful optimization and validation protocols .

How should researchers evaluate the specificity of anti-YHR070C-A antibody for their experimental systems?

Evaluating antibody specificity represents a critical preliminary step when incorporating anti-YHR070C-A antibody into new experimental systems. Researchers should first perform validation experiments using positive controls (samples known to express YHR070C-A) and negative controls (samples where the protein is absent or knocked down). For definitive specificity assessment, consider using a YHR070C-A knockout strain as a negative control if available, as this provides the most stringent test of antibody specificity. Competition assays, where excess purified antigen is pre-incubated with the antibody before application to samples, can help determine if binding is specific to the target protein. Researchers should also validate specificity across different experimental conditions, including various fixation methods, buffer compositions, and detection systems that might be employed in their specific protocols. Documentation of multiple specificity tests should be maintained and reported in publications to enhance reproducibility and confidence in experimental findings.

What are the optimal conditions for using anti-YHR070C-A antibody in Western blot applications?

For optimal Western blot results with anti-YHR070C-A antibody, researchers should implement a carefully optimized protocol addressing several critical parameters. Sample preparation should include efficient yeast cell lysis methods such as glass bead disruption or enzymatic spheroplasting followed by gentle detergent treatment to preserve protein integrity while ensuring complete extraction of the target protein. The protein denaturation step should typically employ reducing conditions (including β-mercaptoethanol or DTT) at 95°C for 5 minutes, though optimization experiments comparing different denaturation temperatures (70-100°C) and durations (3-10 minutes) may be warranted for this specific protein. For gel electrophoresis, a 12-15% polyacrylamide gel is recommended based on the expected molecular weight of the protein, with precision plus protein standards used as size references. During the transfer step, a PVDF membrane often provides better results than nitrocellulose for yeast proteins, with transfer conditions of 100V for 1 hour in a wet transfer system using cold transfer buffer containing 20% methanol. The blocking solution should contain 5% non-fat dry milk in TBST (Tris-buffered saline with 0.1% Tween-20) for 1 hour at room temperature, followed by primary antibody incubation at a dilution of 1:500 to 1:2000 (requiring optimization) overnight at 4°C .

How should researchers optimize ELISA protocols for YHR070C-A detection?

Optimizing ELISA protocols for YHR070C-A detection requires systematic evaluation of multiple parameters to achieve maximum sensitivity and specificity. Begin by determining the optimal coating concentration of capture antibody or antigen, testing a range from 0.5-10 μg/ml in carbonate/bicarbonate buffer (pH 9.6) and incubating overnight at 4°C. Blocking efficiency should be evaluated by comparing different blocking agents (BSA, casein, non-fat milk) at various concentrations (1-5%) and incubation times (1-2 hours at room temperature). For sample preparation, researchers should test different lysis buffers and extraction conditions that efficiently release YHR070C-A while maintaining its native conformation and epitope accessibility. A key optimization step involves titrating the anti-YHR070C-A antibody across a wide dilution range (typically 1:100 to 1:10,000) to determine the concentration that provides maximum specific signal with minimal background. Detection system optimization should include comparison of different enzyme conjugates (HRP vs. AP) and substrate systems (colorimetric, chemiluminescent, fluorescent) to achieve the desired sensitivity and dynamic range. Standard curves using recombinant YHR070C-A protein (if available) should be established to enable accurate quantification, with appropriate curve-fitting models evaluated for their accuracy across the detection range .

How can researchers use anti-YHR070C-A antibody for protein localization studies?

Implementing anti-YHR070C-A antibody for protein localization studies requires specialized immunofluorescence or immunohistochemistry protocols optimized for yeast cells. Begin by evaluating different fixation methods, comparing formaldehyde-based crosslinking (typically 3.7% for 30-60 minutes) with methanol fixation at -20°C, as different proteins may retain epitope accessibility better under specific fixation conditions. Cell wall digestion represents a critical step for yeast samples, typically employing zymolyase or lyticase treatment to create spheroplasts while preserving cellular structures and protein localization patterns. Permeabilization optimization should compare different detergents (Triton X-100, Tween-20, saponin) at various concentrations (0.1-0.5%) and incubation times to allow antibody access while preserving subcellular structures. For specific localization studies, co-staining with established organelle markers is essential—consider using antibodies against proteins known to localize to the nucleus (histone H3), mitochondria (Cox4), endoplasmic reticulum (Kar2), Golgi apparatus (Sec7), or plasma membrane (Pma1) markers to determine YHR070C-A's subcellular distribution. Advanced imaging techniques such as confocal microscopy or super-resolution approaches (STED, PALM, STORM) may be required to precisely determine the spatial relationship between YHR070C-A and various cellular compartments, potentially revealing functional insights based on localization patterns.

What approaches can resolve contradictory results when using anti-YHR070C-A antibody in different experimental contexts?

Resolving contradictory results when using anti-YHR070C-A antibody across different experimental contexts requires systematic troubleshooting and validation approaches. Begin by implementing epitope mapping to identify precisely which regions of the YHR070C-A protein the antibody recognizes, as this information helps determine if certain experimental conditions might mask or alter these epitopes. Researchers should compare multiple antibody lots and potentially source antibodies raised against different epitopes of YHR070C-A to determine if discrepancies result from lot-to-lot variation or epitope-specific effects. Cross-validation using orthogonal detection methods represents a powerful approach—complement antibody-based detection with mass spectrometry, RNA expression analysis (RT-qPCR), or tagged protein expression systems to corroborate findings and identify sources of discrepancy. When contradictions occur between immunoblotting and immunofluorescence results, investigate whether the native versus denatured state of the protein affects epitope accessibility, potentially explaining application-specific differences. Environmental factors such as growth conditions, cell density, and metabolic state can significantly impact protein expression and localization in yeast, necessitating careful standardization of these parameters when comparing results across experiments.

How can researchers adapt immunoprecipitation protocols for studying YHR070C-A protein interactions?

Adapting immunoprecipitation (IP) protocols for studying YHR070C-A protein interactions requires optimization of several critical parameters to preserve physiologically relevant protein complexes while minimizing artifacts. Begin by evaluating different cell lysis approaches, comparing mechanical disruption methods (glass beads, sonication) with enzymatic spheroplasting followed by gentle detergent lysis to determine which approach best preserves native protein interactions while effectively releasing YHR070C-A from cellular compartments. Buffer composition optimization represents a crucial step—test various buffers containing different salt concentrations (50-300 mM NaCl), detergent types and concentrations (0.1-1% NP-40, Triton X-100, or digitonin), and stabilizing agents (glycerol, specific protease inhibitor cocktails optimized for yeast) to identify conditions that maintain interactions while reducing non-specific binding. For antibody-coupling strategies, compare different approaches including direct binding to protein A/G beads, covalent coupling to activated supports, or biotinylated antibody capture on streptavidin matrices to identify the method providing optimal target capture with minimal antibody leaching. Consider implementing stringency gradients during wash steps, progressively increasing salt or detergent concentrations to differentiate between high-affinity specific interactions and weaker non-specific associations. For elution, compare different strategies including low pH, high salt, competitive elution with excess antigen, or direct boiling in SDS sample buffer, selecting the approach that efficiently releases the target complex while maintaining the integrity of interacting proteins for downstream analysis.

How should researchers quantify and normalize Western blot data when studying YHR070C-A expression?

Accurate quantification and normalization of Western blot data for YHR070C-A expression requires implementation of rigorous analytical approaches to ensure reliable and reproducible results. Begin by using digital image capture systems rather than film-based detection, as digital platforms offer superior linear dynamic range necessary for accurate quantification across a wide range of protein abundances. For band intensity measurement, utilize specialized software such as ImageJ, Image Studio, or similar platforms that allow precise definition of regions of interest and background subtraction using rolling ball or local background methods appropriate for yeast protein samples. Multiple normalization strategies should be employed and compared, including normalization to total protein (measured by stain-free technology, Ponceau S, or SYPRO Ruby staining) and reference to housekeeping proteins (such as Act1, Pgk1, or Taf10 in yeast) chosen based on their stability under your specific experimental conditions. When analyzing multiple samples across different blots, researchers should implement inter-blot calibration using common reference samples loaded on each gel to account for transfer efficiency variations and detection system fluctuations. Statistical analysis should incorporate data from at least three biological replicates, with appropriate statistical tests (t-tests, ANOVA, or non-parametric alternatives) applied based on data distribution characteristics and experimental design.

What approaches should researchers use to validate YHR070C-A antibody specificity in their specific experimental systems?

Validating YHR070C-A antibody specificity in specific experimental systems requires implementation of multiple complementary approaches to ensure reliable research outcomes. Begin with genetic validation by comparing signal between wild-type strains and YHR070C-A deletion mutants, which should demonstrate complete signal loss in knockout samples across all applications. Peptide competition assays provide another powerful validation approach—pre-incubating the antibody with excess purified YHR070C-A peptide (the immunogen used for antibody production) should result in signal abolishment if binding is specific. For additional confirmation, researchers should implement orthogonal detection methods, comparing antibody-based detection with mass spectrometry identification, RNA expression correlation, or tagged protein detection using anti-tag antibodies in strains expressing epitope-tagged YHR070C-A. Cross-reactivity assessment should be performed systematically by testing the antibody against closely related yeast proteins, particularly those sharing sequence homology with YHR070C-A, to ensure observed signals derive exclusively from the intended target. Application-specific validation is essential—antibodies performing well in Western blot may not necessarily maintain specificity in immunoprecipitation or immunofluorescence applications due to differences in protein conformation, epitope accessibility, and assay conditions.

How can researchers troubleshoot complex technical problems with YHR070C-A detection in diverse experimental contexts?

Troubleshooting complex technical problems with YHR070C-A detection requires systematic investigation of multiple experimental parameters across different applications. For weak or absent signals in immunoblotting, researchers should implement a methodical optimization approach testing: 1) protein extraction efficiency using different lysis buffers and mechanical disruption methods optimized for yeast cells, 2) protein denaturation conditions varying temperature, time, and reducing agent concentration, 3) transfer efficiency by comparing wet, semi-dry, and specialized high-molecular-weight transfer systems, and 4) detection sensitivity by evaluating different secondary antibodies and visualization methods (chemiluminescence, fluorescence, chromogenic). When encountering high background or non-specific signals, implement a troubleshooting matrix addressing blocking conditions (concentration, composition, time), primary antibody parameters (dilution, incubation time, temperature, diluent composition), and wash stringency (buffer composition, duration, number of washes). For inconsistent results between replicates, investigate sample preparation variability, antibody stability during storage, and lot-to-lot variations by implementing standardized positive controls across experiments. Signal variability between applications (e.g., Western blot versus immunofluorescence) may indicate epitope accessibility issues in different contexts—consider testing alternative fixation and permeabilization conditions or using antibodies targeting different epitopes of YHR070C-A.